Logo image of ANNX

ANNEXON INC (ANNX) Stock Fundamental Analysis

USA - NASDAQ:ANNX - US03589W1027 - Common Stock

3.13 USD
-0.03 (-0.95%)
Last: 10/21/2025, 6:01:52 PM
3.15 USD
+0.02 (+0.64%)
After Hours: 10/21/2025, 6:01:52 PM
Fundamental Rating

2

Taking everything into account, ANNX scores 2 out of 10 in our fundamental rating. ANNX was compared to 534 industry peers in the Biotechnology industry. While ANNX has a great health rating, there are worries on its profitability. ANNX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

ANNX had negative earnings in the past year.
In the past year ANNX has reported a negative cash flow from operations.
ANNX had negative earnings in each of the past 5 years.
In the past 5 years ANNX always reported negative operating cash flow.
ANNX Yearly Net Income VS EBIT VS OCF VS FCFANNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

ANNX's Return On Assets of -71.35% is on the low side compared to the rest of the industry. ANNX is outperformed by 62.17% of its industry peers.
ANNX has a Return On Equity (-94.86%) which is in line with its industry peers.
Industry RankSector Rank
ROA -71.35%
ROE -94.86%
ROIC N/A
ROA(3y)-44.79%
ROA(5y)-39.91%
ROE(3y)-54.04%
ROE(5y)-47.75%
ROIC(3y)N/A
ROIC(5y)N/A
ANNX Yearly ROA, ROE, ROICANNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

ANNX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANNX Yearly Profit, Operating, Gross MarginsANNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, ANNX has more shares outstanding
The number of shares outstanding for ANNX has been reduced compared to 5 years ago.
There is no outstanding debt for ANNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ANNX Yearly Shares OutstandingANNX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ANNX Yearly Total Debt VS Total AssetsANNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ANNX has an Altman-Z score of -2.78. This is a bad value and indicates that ANNX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ANNX (-2.78) is comparable to the rest of the industry.
There is no outstanding debt for ANNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.78
ROIC/WACCN/A
WACCN/A
ANNX Yearly LT Debt VS Equity VS FCFANNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

ANNX has a Current Ratio of 5.67. This indicates that ANNX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 5.67, ANNX is doing good in the industry, outperforming 61.05% of the companies in the same industry.
A Quick Ratio of 5.67 indicates that ANNX has no problem at all paying its short term obligations.
With a decent Quick ratio value of 5.67, ANNX is doing good in the industry, outperforming 61.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.67
Quick Ratio 5.67
ANNX Yearly Current Assets VS Current LiabilitesANNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

1

3. Growth

3.1 Past

ANNX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.88%.
EPS 1Y (TTM)-4.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ANNX will show a very strong growth in Earnings Per Share. The EPS will grow by 31.72% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-37.23%
EPS Next 2Y-14.52%
EPS Next 3Y5.55%
EPS Next 5Y31.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANNX Yearly Revenue VS EstimatesANNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ANNX Yearly EPS VS EstimatesANNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ANNX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANNX Price Earnings VS Forward Price EarningsANNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANNX Per share dataANNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.52%
EPS Next 3Y5.55%

0

5. Dividend

5.1 Amount

No dividends for ANNX!.
Industry RankSector Rank
Dividend Yield N/A

ANNEXON INC

NASDAQ:ANNX (10/21/2025, 6:01:52 PM)

After market: 3.15 +0.02 (+0.64%)

3.13

-0.03 (-0.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-12 2025-11-12
Inst Owners93.23%
Inst Owner Change0.02%
Ins Owners0.57%
Ins Owner Change2.15%
Market Cap343.96M
Analysts84.29
Price Target11.83 (277.96%)
Short Float %9.4%
Short Ratio5.79
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.77%
Min EPS beat(2)-22.39%
Max EPS beat(2)8.85%
EPS beat(4)2
Avg EPS beat(4)-7.11%
Min EPS beat(4)-22.39%
Max EPS beat(4)8.85%
EPS beat(8)6
Avg EPS beat(8)5.97%
EPS beat(12)10
Avg EPS beat(12)9.8%
EPS beat(16)11
Avg EPS beat(16)7.49%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.03%
EPS NY rev (1m)1.01%
EPS NY rev (3m)5.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.73
P/tB 1.73
EV/EBITDA N/A
EPS(TTM)-1.29
EYN/A
EPS(NY)-1.34
Fwd EYN/A
FCF(TTM)-1.42
FCFYN/A
OCF(TTM)-1.42
OCFYN/A
SpS0
BVpS1.81
TBVpS1.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -71.35%
ROE -94.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.79%
ROA(5y)-39.91%
ROE(3y)-54.04%
ROE(5y)-47.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.83%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.67
Quick Ratio 5.67
Altman-Z -2.78
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)106.39%
Cap/Depr(5y)92.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.83%
EPS Next Y-37.23%
EPS Next 2Y-14.52%
EPS Next 3Y5.55%
EPS Next 5Y31.72%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-58.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-53.54%
EBIT Next 3Y-8.46%
EBIT Next 5YN/A
FCF growth 1Y-22.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22.74%
OCF growth 3YN/A
OCF growth 5YN/A